The Hong Kong International Biotechnology Forum and Exhibition (BIOHK2024), organized by the Hong Kong Biotechnology Organization, was successfully held at the Hong Kong Convention and Exhibition Centre (HKCEC) on 11-14 September 2024. It is one of Asia’s largest international biotechnology conventions which aims to facilitate the exchange of ideas among international industry players and foster biotechnology innovation in Hong Kong. Lee's Pharmaceutical (HK) Limited ("Lee's Pharm" or the "Group", HKEx:00950), as a Silver Sponsor, continued to support the event.

The 2024 China Medical and Health Industry Symbiosis Conference, organized by Menet, a healthcare information platform, was grandly held in Huzhou from 25 to 28 June, 2024. A number of lists were released during the conference, including the “China Pharmaceutical Industry Top 100 Series List” and the “Most Valuable Product in Partnership for Drug Store Chain”.

May 30, 2024, Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) grandly held the launch ceremony at its Guangzhou Nansha site for its new product Adapalene and Clindamycin Hydrochloride Gel. The Group’s Managing Director, Ms. Wanee Leelalertsuphakun, and staff members of different departments were present at the event to jointly witness the start of a new chapter in acne treatment marked by the product.

Recently, the "Symposium on the Progress of Nitric Oxide Inhalation Therapy in Newborns" organized by the Shanghai Caritas Foundation took place at the Guangzhou Southern Airlines Pearl Airport Hotel. During the conference, Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) held a launch event for its new rare disease products, Nitric Oxide for Inhalation (INOmax®) and INOmax DSIR Plus Delivery System.

May 15, 2024, the high-profile 88th PharmChina was grandly opened at the Shanghai National Exhibition and Convention Center. As a significant event in the industry, the exhibition attracted 150,000 visitors and brought together nearly 4,000 pharmaceutical companies to showcase their latest products and technological achievements. Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) participated in the event.

Recently, the Guangdong High-tech Association granted the certificates of “Guangdong Prominent High-tech Products” for 2023. The Azilsartan Tablets, an in-house developed product of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950), won the award by virtue of its outstanding innovation capacity, advanced technology, reliable quality and good market prospect.

Recently, the Hefei Municipal Department of Economy and Information Technology announced the list of “Safe Enterprises” for the year 2023. After several rounds of selection, Zhaoke Pharmaceutical (Hefei) Company Limited (“Zhaoke-Hefei”), a subsidiary of Lee's Pharmaceutical Holdings Limited (“Lee’s Pharm” or the “Group”, HKEx:00950), has been honored with this title.

Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) attained the Caring Company Award Logo by The Hong Kong Council of Social Service (HKCSS) for four consecutive years in recognition of its commitment to caring for the community, employees and environment.

January 15, 2024, Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) announced that its in-house developed product Socazolimab Injection, was successfully launched in China and was distributed from its Guangzhou Nansha manufacturing site across the country.

Hong Kong, December 22, 2023, the “STEM Experience Program for Secondary Students——Kanya Lee Scholarship Recognition Ceremony 2023” was successfully held in Hyatt Regency Hong Kong, Tsim Sha Tsui. Established in 2021, the Kanya Lee Scholarship Program, co-organized with Caritas School Social Work Service, aims at providing support to secondary students with economic burden and interest in scientific research to fully develop their potentials and talents, as well as to explore their future. The program has been implemented for three years, with a view to creating an equal education environment, helping disadvantaged students, and promoting social inclusion and development!

28 November 2023, Lee's Pharmaceutical Holdings Limited ("Lee's Pharm" or the "Group", HKEx:00950) announced that the Drug Registration Certificate for Adasuve® (Loxapine for Inhalation) had been obtained from the China National Medical Products Administration (“NMPA”) for the acute treatment of agitation associated with schizophrenia or bipolar disorder in adults.

11 November 2023, the “Rare Diseases Symposium” organized by Rare Disease Hong Kong (RDHK) was successfully held with the theme of "Healthy China, leaving no one behind: how Hong Kong can keep up the pace of the Mainland’s rare disease policy". The symposium brought together experts in the field of rare diseases, representatives from the biotechnology sector and rare disease patients/caregivers from Hong Kong and the Mainland, to explore how Hong Kong can draw on the progress made in the Mainland to proactively address the challenges of rare diseases and to provide better diagnosis, treatment and support to patients. Dr LI Xiaoyi, founder of Lee's Pharmaceutical Holdings Limited ("Lee's Pharm" or the "Group", HKEx:00950), was invited to participate in the expert discussion session of the symposium.